Abstract
Killer immunoglobulin-like receptor (KIR) and KIR-ligand (KIRL) interactions play an important role in natural killer cell mediated graft versus leukemia effect (GVL) after hematopoietic stem cell transplant (HCT) for AML. Mathematically accounting for KIR-KIRL interactions may identify donors with optimal NK cell mediated alloreactivity and GVL. In this retrospective study of 2359 donor recipient pairs (DRP) who underwent unrelated donor (URD) HCT for AML, KIR-KIRL interaction scores were determined. Relapse risk was significantly reduced in donor-recipient pairs (DRP) with higher inhibitory KIR-KIRL interaction and missing KIRL (mKIR) scores, with HR=0.86 (P=0.01) & HR=0.84 (P=0.02) respectively. This effect was not observed with activating KIR-KIRL interactions. The inhibitory KIR-KIRL (iKIR) interaction score components were summed to give an inhibitory-missing ligand (IM-KIR) score, which if it was 5 as opposed to <5, was also associated with a lower relapse risk, SHR 0.8 (P=0.004). Acute and chronic graft vs. host disease (GVHD), survival, GRFS and relapse free survival were not significantly different. However, TRM was increased among those with IM-KIR=5, HR, 1.32 (P=0.01). Among those with HLA matched DRP, anti-thymocyte globulin recipients with IM-KIR=5, had a lower relapse rate HR, 0.61 (p=0.001), however TRM was increased in these patients with a HR, 1.49 (p=0.034). This study demonstrates that unrelated DRPs with high inhibitory KIR content scores confer relapse protection, albeit with increased TRM. Clinical trials utilizing donors with a higher iKIR content in conjunction with novel strategies to reduce TRM should be considered for URD HCT recipients with AML to optimize clinical outcomes.
Highlights Inhibitory and missing KIR-KIRL interactions, both individually and collectively are predictive of relapse following URD HCT for AML.
Amongst 8/8 HLA matched donor recipient pair relapse reduction was observed in those undergoing in vivo T cell depletion with ATG.
TRM is increased in patients with greater magnitude of inhibitory and missing KIR-KIRL interactions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AT was supported by research funding from the NIH-NCI Cancer Center Support Grant (P30-CA016059; PI: Gordon Ginder, MD).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data for this study was completely anonymized by the Center for International Blood and Marrow Transplantation Research and was deemed exempt from IRB review, by the Virginia Commonwealth University IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data are available through the CIBMTR.
